Rajesh Thimmulappa, PhD
Rajesh Thimmulappa, a co-founder of Cureveda, is on the faculty at the Johns Hopkins Bloomberg School of Public Health. Rajesh earned his Ph.D. from the Central Food Technological Research Institute in Mysore, India and joined Johns Hopkins University in 2001 for a postdoctoral fellowship with Shyam Biswal. His main research interest has been to discover host factors that modulate inflammatory signaling responses and protect from immune-inflammatory disorders caused by environmental toxicants and pathogens. He is mainly interested in developing immune-modulators that can be used to improve immune defenses while suppressing inflammation for prevention and early treatment of acute and chronic inflammatory diseases. His research findings lead to identification of Nrf2 as one such host factor which, when targeted by small molecules, improves immune defenses against pathogens as well as dampens inflammation leading to protection from several inflammatory disorders such as COPD, pneumonia, ARDS and sepsis. His other interest is to understand basic mechanisms of how reactive oxygen species and nitric oxide signaling alter innate and T-cell immune responses as well as cross-talk between them.